Supplementary Material for Efficacy of Pazopanib in FGFR1-Amplified Breast Cancer

figshare admin karger published a case report PDF on pazopanib treatment for FGFR1-amplified metastatic breast cancer. The document details a single patient's clinical journey, response metrics, and adverse events from the BELIEVE trial. It was last updated on June 1, 2026.

Use Cases

• Reviewing a clinical case narrative based on patient history and treatment timeline.
• Analyzing response metrics based on CT imaging and serum tumor marker (CEA, CA15-3) data.
• Studying adverse event profiles based on reported manageable side effects.
• Evaluating trial design based on the BELIEVE trial (jRCTs031190104) protocol.

Strengths

• Document provides detailed patient history including age (71), diagnosis (luminal-HER2), and metastasis timeline.
• Includes specific response metrics: partial response after 3 months and progression after 8 months.
• License is CC-BY-4.0, allowing reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data reflects a single case report, limiting statistical power.

Provenance

Source

figshare admin karger

Collection Method

Clinical case report from the BELIEVE trial (NCCH1901).

Freshness

Last updated 2026-06-01 07:15:39; freshness should be verified.